L4 TB6 Getting into Details

Gap fill Part 1

Study Director: Good morning, Jamie. Thank you for _____ me today to _____ the in-vivo PK study we'll be conducting.

Client: Good morning to you too. I'm looking forward to hearing more about your _____ for the study.

Study Director: Great. Let's _____ it then. As we discussed _____ email, we'll be using a mouse model to evaluate the pharmacokinetics of this _____. Since our last discussion, we've reviewed different approaches to _____ the best results, and we propose using a microsampling approach.

Client: I see. We hadn't _____ that. Are you positive that microsampling is _____ go?

Study Director: Yes, it may take _____ longer to develop the analytical method initially, but it will _____ the lab procedures and make the study more efficient to conduct _____. Actually, our team has been _____ this technique in more and more studies over the last couple of years, and we have a _____ group focusing on method development in this _____.

Client: Interesting. Can you _____ me _____ the process?

Study Director: Sure. I'll email you a more detailed _____ shortly, but essentially, we will _____ a catheter into the jugular vein of the mice for blood _____. We'll then administer the drug and collect small blood samples _____. The samples will be stored in a freezer until _____. Once all the samples are collected, we will use LC-MS/MS to analyze them and _____ the PK data.

Client: Are you sure you'll be able to get the same level of _____ with the smaller sample sizes? We'd rather play it safe and go with a _____ sampling method if there's any risk of getting _____ results.